Skip to main content
EJNMMI Research
Download PDF
  • Original research
  • Open access
  • Published:

Increased lesion detectability in patients with locally advanced breast cancer—A pilot study using dynamic whole-body [18F]FDG PET/CT

EJNMMI Research volume 14, Article number: 31 (2024) Cite this article

Abstract

Background

Accurate diagnosis of axillary lymph node (ALN) metastases is essential for prognosis and treatment planning in breast cancer. Evaluation of ALN is done by ultrasound, which is limited by inter-operator variability, and by sentinel lymph node biopsy and/or ALN dissection, none of which are without risks and/or long-term complications. It is known that conventional 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) has limited sensitivity for ALN metastases. However, a recently developed dynamic whole-body (D-WB) [18F]FDG PET/CT scanning protocol, allowing for imaging of tissue [18F]FDG metabolic rate (MRFDG), has been shown to have the potential to increase lesion detectability. The study purpose was to examine detectability of malignant lesions in D-WB [18F]FDG PET/CT compared to conventional [18F]FDG PET/CT.

Results

This study prospectively included ten women with locally advanced breast cancer who were referred for an [18F]FDG PET/CT as part of their diagnostic work-up. They all underwent D-WB [18F]FDG PET/CT, consisting of a 6 min single bed dynamic scan over the chest region started at the time of tracer injection, a 64 min dynamic WB PET scan consisting of 16 continuous bed motion passes, and finally a contrast-enhanced CT scan, with generation of MRFDG parametric images. Lesion visibility was assessed by tumor-to-background and contrast-to-noise ratios using volumes of interest isocontouring tumors with a set limit of 50% of SUVmax and background volumes placed in the vicinity of tumors. Lesion visibility was best in the MRFDG images, with target-to-background values 2.28 (95% CI: 2.04–2.54) times higher than target-to-background values in SUV images, and contrast-to-noise values 1.23 (95% CI: 1.12–1.35) times higher than contrast-to-noise values in SUV images. Furthermore, five imaging experts visually assessed the images and three additional suspicious lesions were found in the MRFDG images compared to SUV images; one suspicious ALN, one suspicious parasternal lymph node, and one suspicious lesion located in the pelvic bone.

Conclusions

D-WB [18F]FDG PET/CT with MRFDG images show potential for improved lesion detectability compared to conventional SUV images in locally advanced breast cancer. Further validation in larger cohorts is needed.

Clinical trial registration

The trial is registered in clinicaltrials.gov, NCT05110443, https://www.clinicaltrials.gov/study/NCT05110443?term=NCT05110443&rank=1.

Background

Breast cancer (BC) is the most common cancer in women and the incidence has been increasing [1]. Axillary lymph node (ALN) metastasis is an important prognostic factor, and the diagnosis of ALN metastases is essential for treatment planning in patients with BC [2]. Evaluation of ALN is done clinically, by ultrasound (US), fine needle aspiration, sentinel lymph node biopsy (SLNB) and ALN dissection (ALND) [3]. As SLNB and ALND are invasive procedures they both carry risks of bleeding, infection, pain, and long-term complications [4,5,6]. Consequently, it is desirable to find alternative ways to examine ALN.

During a conventional 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography / computed tomography (PET/CT), images are generated approximately one hour after tracer injection by a single whole-body (WB) pass. This results in conventional SUV images, where tissue activity is corrected for injected dose and the patient’s body weight. According to current guidelines, [18F]FDG PET/CT may replace traditional imaging, during initial diagnostics of BC with suspicion of metastatic disease [7]. [18F]FDG PET/CT has a higher sensitivity, specificity and accuracy than CT when detecting supraclavicular LN metastases [8]. Furthermore, [18F]FDG PET/CT can be used to guide medical decisions in case of suspicious internal mammary LN where direct biopsy is difficult, as it is more accurate than US [8]. It has also been suggested that [18F]FDG PET/CT staging of the axilla may be useful in some cases of non-suspicious LN on US [9]. However, conventional [18F]FDG PET/CT scans are suboptimal in detecting ALN metastases, with a sensitivity of 54–64% and a specificity of 89–97% [10,11,12,13,14]. Resolution and partial volume effects [15] are major limitations of [18F]FDG PET/CT as a diagnostic tool. Further limitations of the diagnostic performance of PET parameters are attributable to the relatively low [18F]FDG uptake by some BC, such as low grade tumors, invasive lobular carcinomas, tumors with low Ki67 index, and ER+/HER2- tumors [16], and [18F]FDG uptake by benign entities [15, 17, 18]. False negative findings can also be caused by micro-metastases [19].

Attempts have been made to increase the diagnostic accuracy of [18F]FDG PET/CT in detecting ALN metastases. Two studies examined dual-phase [18F]FDG PET/CT, and found that it did not improve the overall diagnostic performance for detecting ALN metastases in patients with BC [20, 21]. Time-of-flight [18F]FDG PET/CT has also been examined and found to have a sensitivity of 85–93% and specificity of 78–88% [19, 22]. Park et al. found that the SUVmax LN to tumor ratio was more accurate in predicting the presence of ALN metastasis than visual assessment and LN SUVmax [23].

Dynamic WB (D-WB) [18F]FDG PET/CT is a recently developed technique involving multiple WB passes, which, in addition to the standard SUV image, can also produce parametric images representing the net uptake rate of tracer into tissue, \({K}_{i}\) [24]. When [18F]FDG is used, the metabolic rate into tissue (MRFDG) can be found by correcting \({K}_{i}\) for the blood glucose level. Where conventional SUV images are a summation of the entire [18F]FDG signal, parametric images enable the distinction between free [18F]FDG and trapped [18F]FDG-6-phosphate. Several studies using dynamic [18F]FDG PET/CT in BC patients have been performed, and associations between kinetic parameters and tumor grade, hormone receptor status, proliferation rate, and nodal status have been reported [25,26,27,28]. However, none of the studies examined whether lesion detectability improved by the addition of parametric images, which remain a question of controversy.

Due to the risk of complications from SLNB and ALND, imaging modalities that enable more accurate classification of ALN as benign or malignant are warranted. [18F]FDG PET/CT is a non-invasive approach, which furthermore has the advantage of being able to evaluate both lesion morphology and glucose metabolism. Therefore, the aim of this pilot study was to examine the detectability of potential malignant lesions, and locoregional LN metastases in particular, in MRFDG images compared to conventional SUV images in patients with locally advanced BC.

Method

Patient population

This prospective single site study included ten women with a mean age of 60 years (range: 40–84 years), all with pathological verified locally advanced BC referred consecutively to [18F]FDG PET/CT as part of their diagnostic work-up. All patients were scanned at Aarhus University Hospital, Denmark, in the period between April 1st 2021 and May 1st 2022. The study protocol was approved by the Central Denmark Region Committees on Health Research Ethics (1-10-72-188-19) and all participants signed an informed consent form.

[18 F]FDG PET/CT

The [18F]FDG PET/CT scan was performed as part of the diagnostic process. Patients fasted for a minimum of 6 h before the administration of [18F]FDG (201–321 MBq). They were all scanned on a Siemens Vision 600 PET/CT in accordance with manufacturer guidelines using the fully automated multiparametric PET acquisition protocol (FlowMotion Multiparametric PET, Siemens Healthineers, Knoxville, USA). The protocol consisted of (i) a low-dose CT for attenuation correction (25 Ref mAs, 120 kV, CareDose4D, CarekV, admire level 4), (ii) a 6 min single bed dynamic scan over the chest region started at the time of tracer injection for extrapolation of an image derived input function (IDIF), (iii) a 64 min dynamic WB PET scan consisting of 16 continuous bed motion passes (7 × 2 min WB passes, followed by 9 × 5 min WB passes), and (iv) a contrast-enhanced CT scan (120 Ref mAs, 120 kV, CareDose4D, admire level 3). This protocol generated both the standard SUV image and additional parametric image. Reconstruction parameters were identical to those used by Dias et al. [24], in short SUV images were normalized to body weight and reconstructed using list-mode data (reconstruction parameters: TrueX + TOF, 4 iterations, 5 subsets, 440 matrices, 2-mm Gaussian filter and relative scatter correction). Parametric images of MRFDG used the nested direct Patlak reconstruction method and were generated with list-mode data from the 6 last passes, i.e. 40–70 min, and the automatically generated IDIF (reconstruction parameters: TrueX + TOF, 8 iterations, 5 subsets, 30 nested loops, 440 matrices, 2-mm Gaussian filter and relative scatter correction).

Kinetics

The parametric image MRFDG is based on the Patlak model [29, 30]. The model assumes unidirectional net transfer of tracer, and can be used in case of irreversible uptake. In the case of [18F]FDG, a two-tissue compartment model with both a reversible and an irreversible compartment is assumed, where the irreversible compartment represents the phosphorylation of [18F]FDG to [18F]FDG-6-phosphate. The Patlak plot becomes linear when the reversible component is in steady-state, and the slope of the line is the rate of net influx, \({K}_{i}\). Metabolic rates were calculated as MRFDG = \({K}_{i}\) ⋅ [glucose]. MRFDG values were calculated for lesions with pathological uptake by indirect image-based analysis in the PKIN module of PMOD® 4.0 (PMOD Technologies Ltd, Zürich, Switzerland) using an irreversible two-tissue compartment model, the 70-min IDIF, and the 70-min activity function from the lesions contained in the bed position covering the chest, and the lumped constant set to 1 (MRFDG(2CM)). MRFDG values were also extracted from lesions by direct reconstruction of parametric images from PET raw data (MRFDG(image)). Direct reconstruction was performed using the Multiparametric PET AI Suite from Siemens Healthineers on data obtained from 40 to 70 min after injection.

Quantitative image analysis

Volume of interest (VOI) outlining was done in the PBAS module from PMOD® 4.0. A VOI was placed manually covering the entire target lesion (breast tumor or metastasis) on both conventional SUV and MRFDG images. Then the isocontouring tool was used for delineation with a set limit to 50% of SUVmax and MRFDG max. Care was taken to ensure that the outlined VOI corresponded to the tumor area and was not affected by other pathology or visual artefacts. Background VOIs were placed in the immediate vicinity of target lesions as an oblong ROI in three consecutive slices. SUVmean was extracted from the conventional PET reconstructions and MRFDG from the parametric image. Time activity curves (TAC) were obtained from the initial 6 min scan of the chest region and the following 16 D-WB passes.

As quantitative measurements of lesion visibility, target-to-background ratio (TBR) and contrast-to-noise ratio (CNR) were used. TBR and CNR were calculated for both SUV (TBR(SUV), CNR(SUV)) and MRFDG (TBR(MRFDG), CNR(MRFDG)) images, and were defined as:

$$TBR=\frac{MEAN\left(target signal\right)}{MEAN\left(background signal\right)}$$
$$CNR=\frac{MEAN\left(target signal\right)- MEAN\left(background signal\right)}{{\sigma }_{background}}$$

Visual image analysis

An expert panel, consisting of four nuclear medicine physicians and one radiologist, all with more than 10 years of experience in PET and CT, examined the images and graded lesions. Two experts (JF and KH) graded lesions using only standard [18F]FDG PET/CT SUV images, while two other experts (AD and LCG) graded lesions using both standard SUV and parametric images (MRFDG and DVFDG). Furthermore, a specialist in radiology (ALJ) inspected the contrast enhanced CT scans.

[18F]FDG PET/CT images (parametric and standard) were inspected using Hermes Gold Client v.2.5.0 (Hermes Medical Solution AB, Stockholm, Sweden). While Philips IntelliSpace Portal (Philips Medical Systems, Amsterdam, Netherlands) was used by the radiologist to examine CT scans. Each lesion was graded according to a certainty score of 1–5, where a score of 5 was given when the physician was confident that the lesion was malignant, 4 when the lesion was most likely malignant, 3 when it could be malignant as well as benign, 2 when it was most likely benign, and 1 when definitely benign. All scans were pseudonymized and readers were not allowed to consults others on image interpretation. Information about clinical stage and pathological results were disclosed to readers prior to inspection of the scans.

Statistical analysis

The normality of the data was checked using QQ-plots. MRFDG values are presented as means with associated 95% confidence intervals (95% CI). MRFDG values from tumors were compared to MRFDG values in glandular breast tissue by a paired t-test. Correlation between MRFDG(2CM) and MRFDG(image) was examined by simple linear regression and Bland-Altman plot was used for visual evaluation of agreement. TBR(MRFDG) values were compared with TBR(SUV) values, and CNR(MRFDG) values with CNR(SUV) values, using log-transformation and paired t-test, results were given as median ratios with 95% CI. Interrater agreement examined the physicians’ certainty score agreement, by the use of intraclass correlation (ICC) estimates and their 95% confidence intervals (CI). ICC was based on absolute-agreement and used a two-way random-effect model [31]. ICC values < 0.5 indicate poor agreement, 0.5–0.75 moderate agreement, 0.75–0.9 good agreement, and > 0.9 excellent agreement [32]. All statistics were calculated using STATA version 17.0 (StataCorp. 2021. Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC).

Results

Baseline

Ten women with BC were included, all referred to a [18F]FDG PET/CT scan for the purpose of staging. Eight patients had newly diagnosed locally advanced BC, defined as clinical stage IIIA-C [33], and two had locally advanced recurrence of BC, clinical stage IIIA-C. For pathological details, see Table 1, and for detailed TNM classification and stage, see supplemental Table S1. They were all scanned with the D-WB PET protocol. Their mean age was 60.1 years (range 40–84 years). Lesions with pathological verification consisted of 11 breast tumors, 11 axillary LN metastases/satellite tumors, and four supraclavicular LN metastases/satellite tumors. Lesions deemed malignant on [18F]FDG PET/CT constituted 13 breast tumors, 39 ALN metastases, 20 other LN metastases, and 13 bone metastases.

Table 1 Pathology
Full size table

Kinetics

TAC for breast tumors and metastases are shown in Fig. 1a. Within the first two min after [18F]FDG injection, there was an activity peak, followed by a swift decrease. From two min and onwards there was a continuous increase. The activity patterns were similar for breast tumors and metastases, although breast tumors tended to have a higher SUVmean. In Fig. 1b it is evident that the activity level in breast tumors was significantly higher compared to background activity in the glandular and adipose tissue of the breast.

Fig. 1
figure 1

Time activity curves from tumor lesions and breast tissue, presented as mean values (standard deviation) of all lesions/tissues from all patients. a) Time activity curves of breast tumors and metastases, b) Time activity curves in breast tumors, breast glandular tissue, and breast adipose tissue

Full size image

The mean MRFDG(image) was 0.17 µmol/min/g (95% CI: 0.11–0.23) for breast tumors, 0.11 µmol/min/g (95% CI: 0.10–0.12) for LN metastases, 0.02 µmol/min/g (95% CI: 0.01–0.02) for normal glandular breast tissue, and 0.002 µmol/min/g (95% CI: 0.001–0.003) for normal adipose breast tissue. There was a statistically significant difference in MRFDG(image) between tumor tissue and glandular breast tissue, p < 0.001. When comparing MRFDG (image) and MRFDG (2CM), we found an excellent correlation, R2 = 0.94 (Fig. 2).

Fig. 2
figure 2

a) Correlation of MRFDG(image) values from direct reconstruction of parametric images from PET raw data and MRFDG(2CM) from indirect image-based analysis. b) Bland-Altman analysis of difference vs. average

Full size image

Quantitative measurement of lesion visibility

TBR(MRFDG) was significantly higher than TBR(SUV), p < 0.001, with TBR(MRFDG) values being 2.25 (95% CI: 1.95–2.52) times higher than the TBR(SUV) values. CNR(MRFDG) was 1.08 (95% CI: 1.01–1.16) times higher than CNR in SUV images, p = 0.02 (Fig. 3). This indicated that lesion detectability was better on the MRFDG images. TBR(MRFDG) values were higher than TBR(SUV) values in 80 lesions out of 85 (94%), while 49 out of 85 (58%) had a higher CNR(MRFDG) compared to CNR(SUV). The lesions with low TBR(MRFDG) and CNR(MRFDG) included all types of tumors; breast tumors, LN metastases, and bone metastases.

Fig. 3
figure 3

Quantitative lesion visibility a) TBR(SUV) vs. TBR(MRFDG) for all lesions in all patients, b) CNR(SUV) vs. CNR(MRFDG) for all lesions in all patients, c) TBR(SUV) vs. TBR(MRFDG) for ALN metastases, d) CNR(SUV) vs. CNR(MRFDG) for ALN metastases

Full size image

Axillary lymph nodes

The same pattern was evident when examining ALN metastases exclusively, here TBR(MRFDG) was 2.19 (95% CI: 2.04–2.35) times higher than TBR(SUV), p < 0.001 (Fig. 3). Notably, TBR(MRFDG) was higher than TBR(SUV) in all ALN metastases.

Visual lesion detectability

There was a moderate interrater agreement in both expert groups. ICC was 0.65 (95% CI: 0.47–0.77) among experts who assessed SUV images and 0.63 (95% CI: 0.44–0.75) among experts who assessed both SUV and MRFDG images (see Table 2 for individual scores). A total of three extra lesions in two patients were detected when both standard SUV and MRFDG images were available (Fig. 4). The three extra lesions detected received different certainty scores. One lesion in the left axillary had a score of four, meaning it was most probable malignant. Two lesions, one parasternal LN and one in the pelvic bone, had certainty scores of five, meaning they were estimated to be malignant. There was consensus among the readers: none of the lesions were identified by those reviewing SUV images, yet both readers examining the MRFDG images classified them as most likely malignant or malignant. Compared to the time of referral, the conventional SUV images increased the disease stage in three patients (Table S1). However, there was no change in disease stage due to the detection of extra lesions in MRFDG images, and none of these lesions were pathologically verified.

Table 2 Certainty scores
Full size table
Fig. 4
figure 4

Additional lesions detected on MRFDG images. a) Parasternal LN, b) Bone lesion in the left ilium in the same patient as a), c) LN lesion in level I of the left axilla

Full size image

The radiology expert who exclusively reviewed the contrast-enhanced CT scans identified fewer lesions in six out of ten scans when compared to the findings from the [18F]FDG PET/CT scans. In two patients, lesions that appeared as a single large lesion on [18F]FDG PET/CT could be distinguished as two and three separate and smaller lesions on the CT scans.

Discussion

This is the first study to examine the diagnostics of D-WB [18F]FDG PET/CT compared to standard WB [18F]FDG PET/CT for the identification of BC lesions, including ALN metastases. The quantitative measures of tumor visibility were consistently higher for TBR(MRFDG) and mostly higher for CNR(MRFDG). This resulted in the detection of three additional suspicious lesions in two out of ten patients when experts examined MRFDG images in addition to the conventional SUV images.

We found an excellent correlation between MRFDG(image) values extracted directly from the image reconstruction generated from PET raw data and MRFDG(2CM) values from the full kinetic analyses made in PMOD® 4.0. These findings suggest that the MRFDG(image) values match and can replace the more comprehensive image-based MRFDG(2CM) calculation, which is in alignment with previous findings [34]. The mean MRFDG values for breast tumors in this study agree with prior results where a significant difference between breast tumors and breast tissue was also observed [25, 27].

As a consequence of the low sensitivity in detecting ALN metastases, [18F]FDG PET/CT scans are primarily used to identify distant metastases. We aimed to evaluate any added value of MRFDG images in the detection of tumor lesions, with a particular emphasis on axillary and parasternal LN metastases, in patients with locally advanced BC. Conventional SUV images are used in the initial staging of numerous cancer types [35]. In recent years, new scanning techniques have enabled the production of D-WB PET/CT scans feasible in a clinical setting and automated reconstruction algorithms can easily produce MRFDG images from PET raw data [24]. Furthermore, with the recent introduction of total-body PET scanners, better dynamic images with reduced noise are now a possibility. To quantitatively evaluate the added value of MRFDG images, TBR and CNR were examined. For this, SUVmean from a VOI outlined by a set limit of 50% of maximum was utilized instead of alternative SUV metrics such as SUVmax or SUVpeak. This method was selected to maintain consistency with prior related studies and to adhere to established guidelines for defining tumor VOIs [24, 36]. We found TBR(MRFDG) to be highest in 80 lesions out of 85 (94%), as a result of the reduced signal from the background. This is in agreement with a study examining 18 patients referred for staging or restaging of abdominal or lung lesions by [18F]FDG PET/CT [37]. Likewise, it has been reported that TBR in MRFDG images is superior to TBR in SUV images in 299/310 lesions (96%) [24]. CNR, which also account for background noise, was highest in MRFDG images in 49 of 85 lesions (58%). This indicated that, in just about 60% of cases MRFDG images have the potential to aid in lesion detection. A proportion that others have reported to be even greater [37].

In the visual assessment of images there was moderate agreement between the two experts assessing the conventional SUV images and the experts who, in addition, also assessed MRFDG images. This is similar to previously reported interrater agreements in [18F]FDG PET/CT assessments in patients with BC and other cancer types [38, 39]. In Prior studies, examining the potential clinical benefits gained by addition of parametric images Dias et al. examined the visual detectability of pathological lesions in MRFDG compared to standard SUV images in a mixed cohort of 101 patients and found no additional lesions on MRFDG images [24]. In a later study, normal values for [18F]FDG uptake in selected tissues were estimated and no difference was observed between malignant and non-malignant [18F]FDG avid lesions in MRFDG images [34]. In contrast to this, a study examining 135 LN in 29 patients with lung cancer found that \({K}_{i}\) values could discriminate malignant from benign LN [40], while an additional, pathological verified, liver lesion was detected in a population of 18 oncological patients [37]. In the present study, the assessment of MRFDG images resulted in the identification of two extra potential locoregional LN metastasis, one in the axillary level I and one located parasternal. This highlights the potential for increased sensitivity in the detection of LN metastases through the utilization of parametric imaging. However, the possibility of eliminating SLNB and ALND remains distant due to the possible presence of micrometastases, sometimes limited [18F]FDG uptake in BC, and the spatial resolution limits of both traditional and parametric PET/CT scans. Nonetheless, the use of more cancer specific tracers, such as [68Ga]FAPI, which has demonstrated encouraging outcomes in BC [41], could enhance the detectability of lesions to some extent. MRFDG images also revealed an additional bone metastasis. The three lesions were all assigned certainty scores of four or five, meaning the expert readers deemed it malignant or most probable malignant. Nevertheless, none of the additional findings led to an alteration in the disease stage, as there was already evidence of metastasis at the same axillary level or distant metastasis observed in conventional SUV images. It has been reported that parametric imaging can reduce the number of false-positive findings [24, 37]. We were unable to investigate this, as all lesions seen on SUV images were also present on MRFDG images. However, as conventional [18F]FDG PET/CT already have a high specificity in BC patients, it is unlikely that this will, in itself, lead to alterations in recommendations.

In line with current knowledge, conventional SUV images were superior to contrast-enhanced CT scans in the detection of tumors [8]. However, in one area, the lungs, CT scans are known to have a higher sensitivity [42]. None of the included patients had any visual lung metastases, hence we were unable to evaluate detection of lung abnormalities. In two patients, the heightened resolution of the contrast-enhanced CT scans, resulted in the differentiation of what appeared to be a single large lesion on [18F]FDG PET/CT into two and three smaller separate lesions.

This study has limitations. First, being a pilot study, our population was small, comprising only ten patients, and heterogeneous, with both newly diagnosed and recurrent BC. However, the enrolled patients were known to have clinical advanced disease and as such a relatively large number of relevant lesions were present for the analysis. We were unable to match LN evaluated by [18F]FDG PET/CT with those that underwent pathologic examination in a one-to-one manner. However, comparison of final stage from [18F]FDG PET/CT results matched the results from the combined diagnostic pathology and imaging reports. As a major limitation, none of the three additional lesions detected on MRFDG images were referred for pathological verification, as this would have had no effect on disease stage. The prolonged scan protocol did not result in motion artifacts. Despite this, an imaging protocol of 70 min will most likely lead to increased patient discomfort with possible motion artifacts as a result. Furthermore, an imaging protocol of 70 min will be incompatible with the increasing demand for PET/CT scans. As a consequence, a reduction in scan time is crucial and it has been proven possible to reduce the D-WB parametric imaging protocols to 20 min by using a population-based input function [43].

Conclusions

In conclusion, this study underlines the potential of increased diagnostic accuracy using D-WB [18F]FDG PET/CT compared to conventional WB [18F]FDG PET/CT, resulting from parametric imaging conducted as an addition to conventional SUV images. These results need to be validated prospectively in a larger cohort where pathological verification is essential.

Data availability

The data used in the current study is available from the corresponding author on reasonable request.

Abbreviations

BC:

Breast cancer

ALN:

Axillary lymph node

US:

Ultrasound

SLNB:

Sentinel lymph node biopsy

ALND:

Axillary lymph node dissection

[18F]FDG:

2-deoxy-2-[18F]fluoro-D-glucose

PET/CT:

Positron emission tomography / computed tomography

D-WB:

Dynamic whole-body

VOI:

Volume of interest

TAC:

Time activity curves

TBR:

Target-to-background ratio

CNR:

Contrast-to-noise ratio

ICC:

Intraclass correlation

CI:

Confidence intervals

References

  1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33.

    Article  PubMed  Google Scholar 

  2. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1194–220.

    Article  CAS  PubMed  Google Scholar 

  3. Brackstone M, Baldassarre FG, Perera FE, Cil T, Mac Gregor MC, Dayes IS, et al. Management of the Axilla in early-stage breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline. J Clin Oncol. 2021;39:3056–82.

    Article  PubMed  Google Scholar 

  4. Schulze T, Mucke J, Markwardt J, Schlag PM, Bembenek A. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection. J Surg Oncol. 2006;93:109–19.

    Article  PubMed  Google Scholar 

  5. Verbelen H, Gebruers N, Eeckhout FM, Verlinden K, Tjalma W. Shoulder and arm morbidity in sentinel node-negative breast cancer patients: a systematic review. Breast Cancer Res Treat. 2014;144:21–31.

    Article  PubMed  Google Scholar 

  6. Verbelen H, Tjalma W, Meirte J, Gebruers N. Long-term morbidity after a negative sentinel node in breast cancer patients. Eur J Cancer Care (Engl). 2019;28:1–8.

    Article  Google Scholar 

  7. Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer ☆. Ann Oncol. 2021;32:1475–95.

    Article  CAS  PubMed  Google Scholar 

  8. Chung HL, Shin K, Sun J, Leung JWT. Extra-axillary nodal metastases in breast cancer: comparison of ultrasound, MRI, PET/CT, and CT. Clin Imaging. 2021;79:113–8.

    Article  PubMed  Google Scholar 

  9. Davidson T, Shehade N, Nissan E, Sklair-Levy M, Ben-Haim S, Barshack I et al. PET/CT in breast cancer staging is useful for evaluation of axillary lymph node and distant metastases. Surg Oncol [Internet]. 2021;38:101567. https://doi.org/10.1016/j.suronc.2021.101567.

  10. Riegger C, Koeninger A, Hartung V, Otterbach F, Kimmig R, Forsting M, et al. Comparison of the diagnostic value of FDG-PET/CT and axillary ultrasound for the detection of lymph node metastases in breast cancer patients. Acta Radiol. 2012;53:1092–8.

    Article  PubMed  Google Scholar 

  11. Liang X, Yu J, Wen B, Xie J, Cai Q, Yang Q. MRI and FDG-PET/CT based assessment of axillary lymph node metastasis in early breast cancer: a meta-analysis. Clin Radiol. 2017;72:295–301.

    Article  CAS  PubMed  Google Scholar 

  12. Robertson IJ, Hand F, Kell MR. FDG-PET/CT in the staging of local/regional metastases in breast cancer. Breast [Internet]. 2011;20:491–4. https://doi.org/10.1016/j.breast.2011.07.002.

  13. Zhang X, Liu Y, Luo H, Zhang J. PET/CT and MRI for identifying Axillary Lymph Node metastases in breast Cancer patients: systematic review and Meta-analysis. J Magn Reson Imaging. 2020;52:1840–51.

    Article  PubMed  Google Scholar 

  14. Kitajima K, Fukushima K, Miyoshi Y, Katsuura T, Igarashi Y, Kawanaka Y, et al. Diagnostic and prognostic value of 18F-FDG PET/CT for axillary lymph node staging in patients with breast cancer. Jpn J Radiol. 2016;34:220–8.

    Article  CAS  PubMed  Google Scholar 

  15. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48:932–45.

    Article  PubMed  Google Scholar 

  16. Groheux D, Hindie E. Breast cancer: initial workup and staging with FDG PET/CT. Clin Transl Imaging [Internet]. 2021;9:221–31. https://doi.org/10.1007/s40336-021-00426-z.

  17. Zangheri B, Messa C, Picchio M, Gianolli L, Landoni C, Fazio F. PET/CT and breast cancer. Eur J Nucl Med Mol Imaging. 2004;31.

  18. Hyo SL, Yoon W, Tae WC, Jae KK, Jin GP, Heoung KK, et al. FDG PET/CT for the detection and evaluation of breast diseases: usefulness and limitations. Radiographics. 2007;27:197–214.

    Article  Google Scholar 

  19. Ferdova E, Baxa J, Naršanska A, Ondřej HES, Fínek J, Topolčan O, et al. Low-dose high-resolution18F-FDG-PET/CT using time-of-flight and point-spread function reconstructions: a role in the detection of breast carcinoma axillary lymph node metastases. Anticancer Res. 2018;38:4145–8.

    Article  CAS  PubMed  Google Scholar 

  20. Sasada S, Masumoto N, Kimura Y, Kajitani K, Emi A, Kadoya T, et al. Identification of axillary lymph node metastasis in patients with breast cancer using dual-phase FDG PET/CT. Am J Roentgenol. 2019;213:1129–35.

    Article  Google Scholar 

  21. Choi WH, Yoo IR, O JH, Kim SH, Chung SK. The value of dual-time-point 18F-FDG PET/CT for identifying axillary lymph node metastasis in breast cancer patients. Br J Radiol. 2011;84:593–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Mori M, Fujioka T, Katsuta L, Tsuchiya J, Kubota K, Kasahara M, et al. Diagnostic performance of time-of-flight PET/CT for evaluating nodal metastasis of the axilla in breast cancer. Nucl Med Commun. 2019;40:958–64.

    Article  CAS  PubMed  Google Scholar 

  23. Park J, Byun BH, Noh WC, Lee SS, Kim HA, Kim EK, et al. Lymph node to primary tumor SUV ratio by 18F-FDG PET/CT and the prediction of axillary lymph node metastases in breast cancer. Clin Nucl Med. 2014;39:249–53.

    Article  Google Scholar 

  24. Dias AH, Pedersen MF, Danielsen H, Munk OL, Gormsen LC. Clinical feasibility and impact of fully automated multiparametric PET imaging using direct patlak reconstruction: evaluation of 103 dynamic whole-body 18F-FDG PET/CT scans. Eur J Nucl Med Mol Imaging. 2021;48:837–50.

    Article  PubMed  Google Scholar 

  25. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Charlop A, Lawton TJ, et al. Blood Flow and Metabolism in locally advanced breast Cancer: relationship to response to Therapy. J Nucl Med. 2002;43:500–9.

    PubMed  Google Scholar 

  26. Dunnwald LK, Doot RK, Specht JM, Gralow JR, Ellis GK, Livingston RB, et al. PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake. Clin Cancer Res. 2011;17:2400–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Kajáry K, Lengyel Z, Tőkés AM, Kulka J, Dank M, Tőkés T. Dynamic FDG-PET/CT in the initial staging of primary breast Cancer: clinicopathological correlations. Pathol Oncol Res. 2020;26:997–1006.

    Article  PubMed  Google Scholar 

  28. Sundaraiya S, Raja T, Nangia S, Sirohi B, Patil S. Role of dynamic and parametric whole-body FDG PET/CT imaging in molecular characterization of primary breast cancer: a single institution experience. Nucl Med Commun. 2022;43:1015–25.

    Article  CAS  PubMed  Google Scholar 

  29. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1–7.

    Article  CAS  PubMed  Google Scholar 

  30. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations J Cereb Blood Flow Metab. 1985;5:584–90.

    Article  CAS  PubMed  Google Scholar 

  31. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86:420–8.

    Article  CAS  PubMed  Google Scholar 

  32. Koo TK, Li MY. A Guideline of selecting and reporting Intraclass correlation coefficients for Reliability Research. J Chiropr Med. 2016;15:155–63.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Teichgraeber DC, Guirguis MS, Whitman GJ. Breast cancer staging: Updates in the AJCC cancer staging manual, 8th edition, and current challenges for radiologists, from the AJR special series on cancer staging. Am J Roentgenol. 2021;217:278–90.

  34. Dias AH, Hansen AK, Munk OL, Gormsen LC. Normal values for 18F-FDG uptake in organs and tissues measured by dynamic whole body multiparametric FDG PET in 126 patients. EJNMMI Res. 2022;12.

  35. Salaün PY, Abgral R, Malard O, Querellou-Lefranc S, Quere G, Wartski M, et al. Good clinical practice recommendations for the use of PET/CT in oncology. Eur J Nucl Med Mol Imaging. 2020;47:28–50.

    Article  PubMed  Google Scholar 

  36. Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.

    Article  CAS  PubMed  Google Scholar 

  37. Fahrni G, Karakatsanis NA, Di Domenicantonio G, Garibotto V, Zaidi H. Does whole-body patlak 18F-FDG PET imaging improve lesion detectability in clinical oncology? Eur Radiol. 2019;29:4812–21.

    Article  PubMed  Google Scholar 

  38. Suzuki A, Nakamoto Y, Terauchi T, Kawamoto M, Okumura Y, Suzuki Y, et al. Inter-observer variations in FDG-PET interpretation for cancer screening. Jpn J Clin Oncol. 2007;37:615–22.

    Article  PubMed  Google Scholar 

  39. Sørensen JS, Vilstrup MH, Holm J, Vogsen M, Bülow JL, Ljungstrøm L et al. Interrater agreement and reliability of percist and visual assessment when using 18f-fdg-pet/ct for response monitoring of metastatic breast cancer. Diagnostics. 2020;10.

  40. Wumener X, Zhang Y, Wang Z, Zhang M, Zang Z, Huang B, et al. Dynamic FDG-PET imaging for differentiating metastatic from non-metastatic lymph nodes of lung cancer. Front Oncol. 2022;12:1–11.

    Article  Google Scholar 

  41. Kömek H, Can C, Güzel Y, Oruç Z, Gündoğan C, Yildirim ÖA, et al. 68Ga-FAPI-04 PET/CT, a new step in breast cancer imaging: a comparative pilot study with the 18F-FDG PET/CT. Ann Nucl Med. 2021;35:744–52.

    Article  PubMed  Google Scholar 

  42. Groheux D, Cochet A, Humbert O, Alberini JL, Hindié E, Mankoff D. 18F-FDG PET/CT for staging and restaging of breast cancer. J Nucl Med. 2016;57:S17–26.

    Article  Google Scholar 

  43. Dias AH, Smith AM, Shah V, Pigg D, Gormsen LC, Munk OL. Clinical validation of a population-based input function for 20-min dynamic whole-body 18F-FDG multiparametric PET imaging. EJNMMI Phys. 2022;9.

Download references

Acknowledgements

Not applicable.

Funding

MAP received financial support from Aarhus Universitets Forskningsfond (AUFF-E-2017-7-17), Faculty of Health, Aarhus University, Aarhus, Denmark and the Steno Diabetes Centre Aarhus (SDCA), Denmark, which is partially funded by an unrestricted donation from the Novo Nordisk Foundation.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Palle Juul-Jensens Boulevard 165, Aarhus, Denmark

    Mette Abildgaard Pedersen, André H. Dias, Karin Hjorthaug, Lars C. Gormsen, Joan Fledelius, Ole Lajord Munk & Mikkel Holm Vendelbo

  2. Department of Biomedicine, Aarhus University, Aarhus, Denmark

    Mette Abildgaard Pedersen & Mikkel Holm Vendelbo

  3. Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark

    Mette Abildgaard Pedersen & Mikkel Holm Vendelbo

  4. Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

    Lars C. Gormsen, Signe Borgquist, Trine Tramm & Ole Lajord Munk

  5. Department of Radiology, Aarhus University Hospital, Aarhus, Denmark

    Anna Lyhne Johnsson

  6. Department of Oncology, Aarhus University Hospital, Aarhus, Denmark

    Signe Borgquist

  7. Department of Pathology, Aarhus University Hospital, Aarhus, Denmark

    Trine Tramm

Authors
  1. Mette Abildgaard Pedersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. André H. Dias
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karin Hjorthaug
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lars C. Gormsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Joan Fledelius
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anna Lyhne Johnsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Signe Borgquist
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Trine Tramm
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ole Lajord Munk
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mikkel Holm Vendelbo
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Concept and design: MAP, MHV. Collection of data: MAP, AHD, KH, LCG, JF, ALJ, TT. Software: AHD, OLM. Statistical analysis: MAP. Interpretation of data: MAP, AHD, KH, LCG, JF, ALJ, SB, TT, OLM, MVH. Writing first manuscript draft: MAP, MHV. Manuscript revision and approval of final manuscript: MAP, AHD, KH, LCG, JF, ALJ, SB, TT, OLM, MVH.

Corresponding author

Correspondence to Mette Abildgaard Pedersen.

Ethics declarations

Ethics approval and consent to participate

The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments and was approved by the Central Denmark Region Committees on Health Research Ethics (1-10-72-188-19) and all participants signed an informed consent form.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pedersen, M.A., Dias, A.H., Hjorthaug, K. et al. Increased lesion detectability in patients with locally advanced breast cancer—A pilot study using dynamic whole-body [18F]FDG PET/CT. EJNMMI Res 14, 31 (2024). https://doi.org/10.1186/s13550-024-01096-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13550-024-01096-4

Keywords